Meeting
2020 ASCO Virtual Scientific Program
Phase Ib/II study of the IDH1-mutant inhibitor ivosidenib with the BCL2 inhibitor venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Presenter
Curtis Andrew Lachowiez, MD
M.D. Anderson Cancer Center
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Oral Abstract Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT03471260
Citation
J Clin Oncol 38: 2020 (suppl; abstr 7500)
DOI
10.1200/JCO.2020.38.15_suppl.7500
Abstract #
7500
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated hematologic malignancies.
Speaker: Curtis Andrew Lachowiez, MD
Videos & Slides
2021 ASCO Annual Meeting
A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.
Speaker: Curtis Andrew Lachowiez, MD
Speaker: Jose Baselga, MD, PhD
Speaker: Panel Discussion